ClinicalTrialsFinder
RecruitingNot ApplicableNCT07817641

Proton Therapy for Mediastinal Lymphoma (PROMLY)

Sponsor

Rigshospitalet, Denmark

Enrollment

139 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin Disease LymphomaMediastinal Lymphoma

Summary

The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Proton therapy for people with diffuse large b-cell lymphoma (dlbcl), hodgkin disease lymphoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONProton therapy

If selected, patients will recieve protontherapy instead of photon therapy

Locations(1)

Dept. of oncology

Copenhagen, Select A State, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07817641

Related Trials

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865168 locations

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

NCT0593408440 locations

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

NCT06594939

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

NCT07788118

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT069801169 locations